Inclusion Criteria:  Patients with rheumatoid arthritis classified by the American College of Rheumatology/European League Against Rheumatism classification criteria  biological disease-modifying anti-rheumatic drug (bDMARD) or targeted synthetic disease-modifying anti-rheumatic drug (tsDMARD) treatment in monotherapy or in combination therapy with conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) in a stable dosage and interval for ≥6 months. Previous extension of bDMARD or tsDMARD interval will also be accepted. bDMARDs and tsDMARDs will include all currently available originator and biosimilar compounds, with the exception of rituximab and its biosimilar compounds No swollen joint by 28-joint count at baseline, and screening C-reactive protein of ≤0.5mg/dL at baseline AND history of C-reactive protein >0,5mg/dl related to rheumatoid arthritis activity Clinical disease activity index ≤10 Shared decision between patient and physician to attempt b/tsDMARD withdrawal Willing and able to understand and follow the study procedures Written informed consent Female and male subjects aged ≥ 18 years  Exclusion Criteria:  History of or current extra-articular manifestation of rheumatoid arthritis, with exception of rheumatoid nodules Systemic glucocorticoid treatment in the past 3 months Intraarticular injection with glucocorticoids in the past 1 month Joint replacement surgery other than total knee or hip arthroplasty or complete joint destruction Power Doppler signal ≥2 in any assessed joint and/or tendon at screening or baseline